To read the full article visit http://seekingalpha.com/article/1870351
Highlighting Galena’s main drug candidate, breast cancer therapy NeuVax, Stock Investor provides a short video sourced from the company’s website demonstrating how the therapy works.
The article also recaps and highlights the value of Galena’s Folate Binding Protein (FBP) vaccine, noting the importance of phase 1 results. In recent phase 1 trial of FBP it was determined that optimal dosage was 500 mcg peptide combined with 250 mcg GM-CSF. The vaccine proved to be well-tolerated and Galena anticipates initiating a phase 2 trial in December.
Stock Investor also discusses additional therapeutic application for Neuvax, Galena’s most recent financial results, and the market potential of Abstral® for breakthrough cancer pain.
“If Abstral were only able to gain 10 percent of the potential U.S. market for TIRFs it would bring in $40 million in revenue. With a 30 percent profit margin based on initial sales, this could bring upwards of $12 million per year in profits to GALE and reduce its need for additional financing,” he writes.
In his conclusion the author writes, “Galena is one of the most interesting biotechnology investments I have uncovered this year. The market potential for the numerous indications the company is focused on is huge. The launch of Abstral in the U.S. will help to fund the GALE pipeline and could have the potential to be a large revenue generator all by itself based on the gains seen in INSY over the last year.”
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
